This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 113/20/2383    most recent CIRCULATIONAHA.105.609420v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sigg, D. C. Articles by Ujhelyi, M. R. Search for Related Content PubMed PubMed Citation Articles by Sigg, D. C. Articles by Ujhelyi, M. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Atrial Fibrillation Related Collections Cardiovascular Pharmacology Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs Related Article

(Circulation. 2006;113:2383-2390.)
© 2006 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Focal Pharmacological Modulation of Atrioventricular Nodal Conduction via Implantable Catheter

A Novel Therapy for Atrial Fibrillation?

Daniel C. Sigg, MD, PhD; Prasanga Hiniduma-Lokuge, MS; James A. Coles, Jr, PhD; Phillip Falkner, DVM; Rebecca Rose, DVM, PhD; Jon F. Urban, PhD; Michael R. Ujhelyi, PharmD

From Medtronic, Inc, Minneapolis, Minn.

Correspondence to Daniel C. Sigg, MD, PhD, Medtronic, Inc, 7000 Central Ave NE, Minneapolis, MN 55432. E-mail daniel.c.sigg{at}medtronic.com

Received December 27, 2005; revision received February 11, 2006; accepted March 2, 2006.

Background— Pharmacological ventricular rate control is an acceptable atrial fibrillation (AF) therapy limited by systemic toxicity. We postulate that focal catheter-based drug delivery into the atrioventricular nodal (AVN) region may effectively control ventricular rate during AF without systemic toxicity. This study evaluated the effects of focally administered acetylcholine on AVN conduction and refractoriness during sinus rhythm and AF.

Methods and Results— Canines (n=7) were anesthetized and instrumented to assess cardiac electrophysiology and blood pressure. A custom drug delivery catheter was implanted in the AVN region. Incremental doses of acetylcholine starting at 10 µg/min were infused until complete AV block was achieved. Acetylcholine induced dose-dependent AV block. AF induction and electrophysiology measurements were performed during baseline and acetylcholine-induced first-degree and third-degree AV block. During AF, infusion of acetylcholine decreased ventricular rates from 182±32 to 77±28 and 28±8 bpm (first-degree and third-degree AV block, respectively; P<0.05). At the first-degree AV block dose, AVN effective refractory period increased from 186±37 to 282±33 ms, and Wenckebach cycle length increased from 271±29 to 378±58 ms (P<0.05). The first-degree AV block dose prolonged AV and AH intervals by 26% and 23% (P<0.05), whereas AA intervals and blood pressure remained unchanged, demonstrating a local effect. All effects were reversed 20 minutes after infusion was stopped.

Conclusions— Focal acetylcholine delivery into the AVN increased AVN refractoriness and significantly decreased ventricular rate response during induced AF in a dose-related, reversible manner without systemic side effects. This may represent a novel therapy for AF whereby ventricular rate is controlled with the use of an implantable drug delivery system.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2006 113: 2373. [Extract] [Full Text]

This article has been cited by other articles:

				P. J. Wang Rate Control: Is Local Better? Circulation, May 23, 2006; 113(20): 2374 - 2376. [Full Text] [PDF]